Latest Chemical pathology Stories

Distinguished scholars to present research and discuss findings using innovative technology prior to American Society of Mass Spectrometry conference SHOREVIEW, Minn., May 17, 2013 /PRNewswire/ -- TSI Incorporated, manufacturer of precision measurement and chemical analysis instrumentation, will host a number of distinguished scholars in an upcoming symposium highlighting an innovative alternative to traditional mass spectrometry techniques prior to the American Society of Mass...

Kantar Health's thought leaders will participate in sessions on oncology and forecasting. New York, NY (PRWEB) May 14, 2013 Kantar Health, a leading global healthcare consulting firm, today announced that three of its thought leaders will present at the 2013 PBIRG Annual General Meeting in Naples, Fla., May 19-22. Gordon Gochenauer, director, will present “Market Dynamics – Interactions and the Changing Landscape” at 2:00pm on Sunday, May 19. This session will explore the...

HCG Lifestyle.com presents its very own list of the three best HCG Drops brand for effective and natural weight loss. Largo, FL (PRWEB) May 13, 2013 As the world faces overweight and obesity issues of epidemic proportions, people are becoming increasingly alarmed and, consequently, conscious about their health. Weight loss is now a serious goal that individuals want to achieve with healthy diet, enough rest and regular exercise. More often than not, however, shedding those excess pounds...

By combining cutting edge nutritional science with expert level diet experience, HCG Lifestyle produces fast weight loss and diet plans capable of resetting the body's metabolism. Largo, FL (PRWEB) May 10, 2013 hCG Lifestyle's Diet Plan Different kinds of diets come out every year and many are willing to try any of these fad diets in the hopes that one of them will be successful at weight loss. According to a statistic from the Centers for Disease Control and Prevention,...

SAN DIEGO, May 10, 2013 /PRNewswire-USNewswire/ -- The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.  This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders. The partnership will integrate Denovo's pharmacogenomic technology into the analysis of biological...

Proof-of-Concept Clinical Study Demonstrating Predictive Power of FirstMark's Aggregate Biomarker Strategy for Predicting Near-Term Myocardial Infarction/Death, Published in JACC SAN DIEGO, May 9, 2013 /PRNewswire-iReach/ -- FirstMark, a division of GenWay Biotech that is focused on developing and commercializing noninvasive diagnostic and health monitoring tests for unmet clinical needs, today announced that results from the break-through proof-of-concept clinical study, performed...

LAUSANNE, Switzerland, April 24, 2013 /PRNewswire/ -- Oncotest GmbH and Debiopharm Group(TM) (Debiopharm) a Swiss-based global biopharmaceutical group, are pleased to announce the successful completion of the first biomarker projects at Oncotest. In a recent study, pharmacological data was generated with Debiopharm's investigational compound in Oncotest's 3D assay system for patient-derived xenografts and correlated with the extensive Oncotest's genomic and transcriptomic...

RICHMOND, Va., April 23, 2013 /PRNewswire/ -- The Lingerfelt Companies, headquartered in Richmond, Virginia (www.LingerfeltCo.com), announce that development has begun on the third phase of BioTech 8, a six-story tower within the 34-acre Virginia BioTechnology Research Park in downtown Richmond. The project will complete this $100 million three-building headquarter complex totaling 276,000 sq. ft. including a four-story, 485-space parking deck. This facility is an expansion for...

DUBLIN, April 22, 2013 /PRNewswire/ -- Research and Markets announces the addition of "2013 Oncology Development Strategies Report [http://www.researchandmarkets.com/research/scsjwb/oncology ]: Considerable Commercial Potential but Specific Needs Must be Addressed" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has...

CASTLE ROCK, Colo., April 18, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, protein biomarker-based assay for appendicitis, today announced the appointment of Stephen A. Williams, M.D., Ph.D., Chief Medical Officer at SomaLogic, to the Company's Board of Directors. Dr. Williams brings his experience in diagnostic imaging and biomarker discovery to the Venaxis...